These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Bortezomib-Induced Cardiac Tamponade in a 49-Year-Old Man. Burkhart T; Keith MCL; Lenneman CAG; Fernando RR Tex Heart Inst J; 2018 Aug; 45(4):260-263. PubMed ID: 30374242 [TBL] [Abstract][Full Text] [Related]
7. Heart failure secondary to carfilzomib-induced heart block in multiple myeloma patients. Tjionas H; Gupta AK J Oncol Pharm Pract; 2017 Mar; 23(2):152-156. PubMed ID: 26786028 [TBL] [Abstract][Full Text] [Related]
8. Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature. Bockorny M; Chakravarty S; Schulman P; Bockorny B; Bona R Acta Haematol; 2012; 128(4):244-7. PubMed ID: 22964848 [TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibitors in the treatment of B-cell malignancies. Schenkein D Clin Lymphoma; 2002 Jun; 3(1):49-55. PubMed ID: 12141956 [TBL] [Abstract][Full Text] [Related]
10. Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas. Paoluzzi L; O'Connor OA BioDrugs; 2006; 20(1):13-23. PubMed ID: 16573348 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy. Iannaccone A; Bruno G; Ravera A; Gay F; Salvini M; Bringhen S; Sabia L; Avenatti E; Veglio F; Milan A High Blood Press Cardiovasc Prev; 2018 Jun; 25(2):209-218. PubMed ID: 29582365 [TBL] [Abstract][Full Text] [Related]
12. Cardiotoxicity associated with bortezomib: A single-center experience. Gurram MK; Pulivarthi S; Ehresmann K; Mathew J J Cancer Res Ther; 2017; 13(6):961-963. PubMed ID: 29237959 [TBL] [Abstract][Full Text] [Related]
13. [Left atrial and ventricular epicardial dual chamber pacing through a left lateral thoracotomy to treat pediatric complete atrioventricular block]. Li XM; Zhang Y; Pan GY; Liu HJ; Li HY; Wu QY Zhonghua Er Ke Za Zhi; 2013 Aug; 51(8):578-83. PubMed ID: 24225287 [TBL] [Abstract][Full Text] [Related]
14. Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma. Grandin EW; Ky B; Cornell RF; Carver J; Lenihan DJ J Card Fail; 2015 Feb; 21(2):138-44. PubMed ID: 25433360 [TBL] [Abstract][Full Text] [Related]
15. A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma. Martin P; Ruan J; Furman R; Rutherford S; Allan J; Chen Z; Huang X; DiLiberto M; Chen-Kiang S; Leonard JP Leuk Lymphoma; 2019 Dec; 60(12):2917-2921. PubMed ID: 31120355 [TBL] [Abstract][Full Text] [Related]
16. Cardiovascular Complications of Proteasome Inhibitors Used in Multiple Myeloma. Cole DC; Frishman WH Cardiol Rev; 2018; 26(3):122-129. PubMed ID: 29077585 [TBL] [Abstract][Full Text] [Related]
17. Complete heart block secondary to bortezomib use in multiple myeloma. Dasanu CA J Oncol Pharm Pract; 2011 Sep; 17(3):282-4. PubMed ID: 20406745 [TBL] [Abstract][Full Text] [Related]
18. Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma. O'Connor OA Clin Lymphoma Myeloma; 2005 Nov; 6(3):191-9. PubMed ID: 16354324 [TBL] [Abstract][Full Text] [Related]
19. Early Steps in Herpes Simplex Virus Infection Blocked by a Proteasome Inhibitor. Schneider SM; Pritchard SM; Wudiri GA; Trammell CE; Nicola AV mBio; 2019 May; 10(3):. PubMed ID: 31088925 [TBL] [Abstract][Full Text] [Related]
20. DANFIN functions as an inhibitor of transcription factor NF-κB and potentiates the antitumor effect of bortezomib in multiple myeloma. Uematsu A; Kido K; Manabe E; Takeda H; Takahashi H; Hayashi M; Imai Y; Sawasaki T Biochem Biophys Res Commun; 2018 Jan; 495(3):2289-2295. PubMed ID: 29284118 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]